Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2014 / Cilt: 23 - Sayı: 3

Kolistin ve akut böbrek yetmezliği: Tek merkez deneyimi

Colistin and acute renal failure: A centre's experience

Pages
196–201
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although colistin is an effective therapeutic agent used for resistant infections, we have to avoid higher doses due to its potential side effect of ARF.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Colistin is a polymyxin antibiotic with a polypeptide structure and is effective against gram-negative bacilli.
📊
Key Findings & Data:Although its use had decreased due to its side effects, it has increased again in recent years, especially for multi-drug resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter and Enterobacteriaceae.
💡
Conclusion & Impact:Although colistin is an effective therapeutic agent used for resistant infections, we have to avoid higher doses due to its potential side effect of ARF.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Colistin is a polymyxin antibiotic with a polypeptide structure and is effective against gram-negative bacilli. Although its use had decreased due to its side effects, it has increased again in recent years, especially for multi-drug resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter and Enterobacteriaceae. In the present study, patients that received colistin at one center were retrospectively analysed in terms of nephrotoxicity. MATERIAL and METHODS: Patients hospitalized and treated with colistin in the intensive care unit between January 2012 and August 2013 were analyzed. Demographic data; biochemical tests at baseline, daily during hospitalization and after discharge; and the initial, maintenance and total doses of colistin were evaluated. RESULTS: The mean age was 62±13 (31-86) years for the 27 patients with 17 (63%) males that were followed-up for an average duration of 63±89 days. During follow-up, 18 patients (66.7%) developed acute renal failure (ARF) and 17 (63%) of died. There were 12 (66.7%) mortalities in the ARF group and 5 (55%) in the group without ARF ( p> 0.05). The total colistin dose and leukocyte count were higher in the ARF group with 3.75±2.34 g and 12.04±5.05/mm3 than the non-ARF group at 3.32±1.86 g and 7.60±3.7/mm3 but did not reach statistical significance. CONCLUSION: ARF increases the mortality in ICU patients. Although colistin is an effective therapeutic agent used for resistant infections, we have to avoid higher doses due to its potential side effect of ARF.

Özet

AMAÇ: Kolistin gram negatif basillerde etkili, polipeptid yapıda bir polimiksin antibiyotiğidir. Geçmişte yan etkileri nedeniyle kullanımı azalmasına karşın son yıllarda özellikle çoklu ilaç direnci olan Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter ve Enterobacteriaceaeda etkinliği olduğundan kullanımı giderek artmaktadır. Bu çalışmada, merkezimizde kolistin kullanılan hastalar nefrotoksisite yönünden retrospektif olarak değerlendirilmiştir. GEREÇ ve YÖNTEMLER: Çalışmaya Ocak 2012 Ağustos 2013 yıllarında 2. basamak yoğun bakım ünitemizde yatarak kolistin tedavisi alan hastalar alındı. Demografik veriler; bazal, yatış sırasında günlük alınan ve taburculuk sonrası bakılan biyokimyasal tetkikler; ve kolistin başlangıç, idame ve toplamda verilen dozları değerlendirildi. BULGULAR: Yaş ortalaması 62±13 (31-86) yıl olan 17 (%63) erkek, toplam 27 hasta ortalama 63±89 gün izlenmiştir. Tüm izlem süresince hastaların 18inde (%66,7) akut böbrek yetmezliği (ABY) gelişmiş, 17 (%63) hasta exitus olmuştur. Mortaliteler ABY grubunda 12 (%66,7), ABY olmayan grupta 5tir (%55) (p> 0,05). Toplam kolistin dozu ve lökosit sayısı istatistiki olarak anlamlılığa ulaşmasa da ABY grubunda 3,75±2,34 g ve 12,04±5,05/mm3 olup ABY olmayan gruptaki 3,32±.1,86 g ve 7,60±3,7/ mm3 değerlerinden daha yüksektir. SONUÇ: Yoğun bakım hastalarında ABY mortaliteyi arttırmaktadır. Kolistin, dirençli enfeksiyonlarda kullanılan etkin bir tedavi ajanı olduğu halde ABY yan etkisi göz önüne alındığında bu ilacın yüksek dozlarda kullanımından mümkün olduğunca kaçınılması doğru bir yaklaşım olacaktır.

🔖

Cite This Article

TAVŞAN, Ö., SEVERCAN, E., KARACA, N., EMİNOĞLU, V., SUNGUR, M., ÇETİNTÜRK, A., DUMAN, S., HÜR, E., PİŞKİNPAŞA, S. (2022). Kolistin ve akut böbrek yetmezliği: Tek merkez deneyimi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 23 - Sayı: 3, 196–201. https://ajindex.com/articles/636311

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Falagas ME, Grammatikos AP, Michalopoulos A: Potential of old- generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008; 6(5): 593-600
  2. Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Ann Rev Biochem 1977;46:723-763 Landman D1, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J: Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007; 60:78-82
  3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10(9): 597-602
  4. Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC: Polymyxin- resistant Acinetobacter spp. isolates: What is next? Emerg Infect Dis 2003; 9(8): 1025-1027
  5. Karbuz A, Ozdemir H, Yaman A, Kocabaş BA, Odek C, Güriz H, Aysev AD, Ciftçi E, Kendirli T, Ateş C, Ince E: The use of colistin in critically ill children in a pediatric intensive care unit. Pediatr Infect Dis J 2014; 33(1): e19-24 Benifla M, Zucker G, Cohen A, Alkan M: Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54(1): 290-292
  6. Yagmur R, Esen F: Intrathecal colistin for treatment of Pseudomonas aeruginosa ventriculitis: Report of a case with successful outcome. Crit Care 2006; 10(6): 428 Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M: Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53(4): 274-278
  7. Karakitsos D, Paramythiotou E, Samonis G, Karabinis A: Is intraventricular colistin an effective and safe treatment for post- surgical ventriculitis in the intensive care unit? Acta Anaesthesiol Scand 2006; 50(10): 1309-1310
  8. Fass RJ, Barnishan J, Ayers LW: Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995; 36(2): 343-353
  9. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E, Sauaia N, Boulos M: An outbreak of multiresistan